Cargando…

Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol

INTRODUCTION: Patients receiving a haematopoietic stem cell transplant (HSCT) are subjected to complex oral medications based on prophylactic and immunosuppressive treatments. Adherence to medication plays a role in survival, and medication non-adherence (MNA) is closely associated with graft-versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Visintini, Chiara, Mansutti, Irene, Palese, Alvisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717329/
https://www.ncbi.nlm.nih.gov/pubmed/36456011
http://dx.doi.org/10.1136/bmjopen-2022-065676
_version_ 1784842880133627904
author Visintini, Chiara
Mansutti, Irene
Palese, Alvisa
author_facet Visintini, Chiara
Mansutti, Irene
Palese, Alvisa
author_sort Visintini, Chiara
collection PubMed
description INTRODUCTION: Patients receiving a haematopoietic stem cell transplant (HSCT) are subjected to complex oral medications based on prophylactic and immunosuppressive treatments. Adherence to medication plays a role in survival, and medication non-adherence (MNA) is closely associated with graft-versus-host disease and other complications. The aim of this systematic review is to summarise the available evidence regarding prevalence rates of medication adherence, the risk factors of MNA, the effectiveness of interventions to increase medication adherence and the outcomes associated with MNA. METHODS AND ANALYSIS: We designed a systematic review according to the Joanna Briggs Institute methodology. We will search the Cochrane Library and the CINAHL, EMBASE, MEDLINE via PubMed, PsycINFO and Scopus databases. We will include published and unpublished primary studies: (a) on humans, from inception until 10 May 2022; (b) written in any language; (c) experimental (randomised and non-randomised), observational (prospective, retrospective cohort and case–control), correlational, cross-sectional and longitudinal; and (d) with a low risk of bias, according to the quality assessment we perform. We will exclude secondary and qualitative studies, protocols, publications without original data, including paediatrics or related to autologous HSCT. The primary outcome will be the prevalence of oral medication adherence; the secondary outcomes will be the risk factors of MNA, the interventions aimed at increasing medication adherence and the outcomes of MNA. Two researchers will independently screen the eligible studies, then extract and describe the data. Disagreements will be resolved by a third researcher. We will provide a qualitative narrative synthesis of the findings. ETHICS AND DISSEMINATION: Ethical approval is not required given that previously published studies will be used. We will disseminate the findings through conference presentations and publications in international peer-reviewed scientific journals. PROSPERO REGISTRATION NUMBER: CRD42022315298.
format Online
Article
Text
id pubmed-9717329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97173292022-12-03 Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol Visintini, Chiara Mansutti, Irene Palese, Alvisa BMJ Open Oncology INTRODUCTION: Patients receiving a haematopoietic stem cell transplant (HSCT) are subjected to complex oral medications based on prophylactic and immunosuppressive treatments. Adherence to medication plays a role in survival, and medication non-adherence (MNA) is closely associated with graft-versus-host disease and other complications. The aim of this systematic review is to summarise the available evidence regarding prevalence rates of medication adherence, the risk factors of MNA, the effectiveness of interventions to increase medication adherence and the outcomes associated with MNA. METHODS AND ANALYSIS: We designed a systematic review according to the Joanna Briggs Institute methodology. We will search the Cochrane Library and the CINAHL, EMBASE, MEDLINE via PubMed, PsycINFO and Scopus databases. We will include published and unpublished primary studies: (a) on humans, from inception until 10 May 2022; (b) written in any language; (c) experimental (randomised and non-randomised), observational (prospective, retrospective cohort and case–control), correlational, cross-sectional and longitudinal; and (d) with a low risk of bias, according to the quality assessment we perform. We will exclude secondary and qualitative studies, protocols, publications without original data, including paediatrics or related to autologous HSCT. The primary outcome will be the prevalence of oral medication adherence; the secondary outcomes will be the risk factors of MNA, the interventions aimed at increasing medication adherence and the outcomes of MNA. Two researchers will independently screen the eligible studies, then extract and describe the data. Disagreements will be resolved by a third researcher. We will provide a qualitative narrative synthesis of the findings. ETHICS AND DISSEMINATION: Ethical approval is not required given that previously published studies will be used. We will disseminate the findings through conference presentations and publications in international peer-reviewed scientific journals. PROSPERO REGISTRATION NUMBER: CRD42022315298. BMJ Publishing Group 2022-12-01 /pmc/articles/PMC9717329/ /pubmed/36456011 http://dx.doi.org/10.1136/bmjopen-2022-065676 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Visintini, Chiara
Mansutti, Irene
Palese, Alvisa
Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title_full Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title_fullStr Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title_full_unstemmed Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title_short Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
title_sort medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717329/
https://www.ncbi.nlm.nih.gov/pubmed/36456011
http://dx.doi.org/10.1136/bmjopen-2022-065676
work_keys_str_mv AT visintinichiara medicationadherenceamongallogeneichaematopoieticstemcelltransplantrecipientsasystematicreviewprotocol
AT mansuttiirene medicationadherenceamongallogeneichaematopoieticstemcelltransplantrecipientsasystematicreviewprotocol
AT palesealvisa medicationadherenceamongallogeneichaematopoieticstemcelltransplantrecipientsasystematicreviewprotocol